IL-23
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al.
C-…
3 years 4 months ago
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read more...
https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
3 years 4 months ago
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC)
Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021.
https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?
Oral presentation (6937) discussed that…
3 years 4 months ago
#EULAR2021 IL-23 & IL-12/23 coverage in one spot on RheumNow.
https://t.co/sut3zubcow https://t.co/f7XDuRyLB9
3 years 4 months ago
No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw
3 years 4 months ago
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
3 years 4 months ago
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW